—A Decision Resources’ Biosimilars Advisory Service Webinar
As part of our Biosimilars Advisory Service, Decision Resources is offering an exclusive webinar entitled What are the Implications of the Recently Announced Patent for Amgen’s Enbrel on the Biosimilar Market Amongst TNF-α Inhibitors? This webinar is open ONLY to subscribers of Decision Resources’ Biosimilars Advisory Service.
Please contact us to learn how you can purchase this service and attend the webinar.
On November 22, 2011, Amgen announced the issuance of a composition of matter patent covering Enbrel (U.S. patent number 8,063,182). The patent covers Enbrel’s protein sequence and means that branded Enbrel could be well-protected from etanercept biosimilar erosion for another 17 years (through 2028) in the United States. The issuance of the Enbrel patent will cause significant concern to biosimilar etanercept manufacturers because of the considerable delay in the possible launch of biosimilar etanercept in the United States. Biosimilar etanercept manufacturers will have to consider strategies to help them minimize potential near-term losses because, before the issuance of this patent, biosimilar etanercept could have launched in 2015 in the United States.
In this presentation, Biosimilars Advisory Service Product Director Andrew Merron, Ph.D., will answer the following questions:
- How can the Enbrel patent be granted for 17 years and how will etanercept biosimilar manufacturers react?
- What are revised sales estimates for branded Enbrel through 2020 in light of the Amgen patent?
- How will biosimilar etanercept achieve market access?
- What will be the impact to brand and biosimilar versions of Janssen Biotech/Merck/Mitsubishi Tanabe/Janssen Pharmaceutical’s Remicade and Abbott/Eisai’s Humira?
- What impact does the patent issuance have on the total biosimilar TNF-α market across the seven major markets?
In addition to discussing the Enbrel patent, this fourth quarter webinar from the Biosimilars Advisory Service will also address other recent news, including the implications of Amgen’s contracts with dialysis chains for the supply of Epogen, new strategic partnerships between biosimilar companies and region-specific biosimilar news from the United States, Europe, Japan and the emerging markets.
Following the presentation, Dr. Merron will conduct a live Q&A.
What are the Implications of the Recently Announced Patent for Amgen’s Enbrel on the Biosimilar Market Amongst TNF-α Inhibitors?
December 15, 2011 at 10 a.m. U.S. Eastern Time, 4 p.m. Central European Time (Paris).
Webinar Details Date & Time Presentation: 30 minutes Q & A: 15 minutes |
About the Speaker
|
Andrew Merron Ph.D., is the Biosimilars Advisory Service Product Director at Decision Resources. Prior to managing the Biosimilars Advisory Service, Dr. Merron was a senior analyst in the oncology department at Decision Resources. Dr. Merron has extensive experience in forecasting oncology and hematology-oncology drug markets. Dr. Merron also has considerable experience in conducting primary research with physicians and payers across the major pharmaceutical markets. Through his analyses, Dr. Merron identifies key market findings and highlights their strategic importance. Prior to joining Decision Resources, Dr. Merron received his B.Sc. in biochemistry from the University of Bath and his Ph.D. in molecular oncology from the University of London. His doctorate focused on in vivo molecular imaging of cancer gene therapies, specifically oncolytic adenoviruses.To learn how you can purchase the Biosimilars Advisory Service and attend the webinar, please contact us using the information below.
In North America: Keith Rourke | 781-993-2656
In Europe: Kaj van Langendonck | +32-2-357-06-14
In Japan: Makiko Yoshimoto | +81-3-5401-2615
Terms of Use | Privacy Policy | Contact Us | Careers
Decision Resources • 8 New England Executive Park • Burlington, MA 01803
You are receiving this email because you have previously requested information from Decision Resources. You can update your email preferences at any time.
© 2011 Decision Resources, LLC. All rights reserved.
